Dr. Bleakley is a pediatric oncologist and HCT physician with an active research interest in the development of new therapies and transplantation strategies to separate the graft-versus-leukemia effect (GVL) from graft-versus-host-disease (GVHD) in order to improve the outcomes of patient with high-risk leukemia.
The Bleakley laboratory focuses on:
The lab has extensive expertise in the isolation, culture, genetic modification, and propagation of antigen-specific T cells, in bioinformatics, genetic and molecular techniques employed for antigen discovery, and in flow cytometry and functional analysis of human T cells for correlative studies of human immunotherapy and HCT clinical trials.
Bleakley is the Sponsor of successful Investigational New Drug applications to the FDA and Principal Investigator of two ongoing and one recently completed clinical trial evaluating depletion of naïve T cells from allogeneic peripheral blood stem cell grafts to prevent GVHD. The research group is also currently completing the development of an adoptive T cell immunotherapy trial involving genetic modification of donor T cells using a lentiviral vector to express a T cell receptor specific for the minor histocompatibility antigen HA-1.